Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genmab Announces Net Sales Results of Darzalex« (Daratumumab) for the Second Quarter of 2021

07/21/2021 | 06:31am EDT

Genmab announced DARZALEX sales results for the second quarter of 2021. For the quarter, the company reported worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,433 million in the second quarter of 2021. Net trade sales were USD 770 million in the U.S. and USD 663 million in the rest of the world.


ę S&P Capital IQ 2021
All news about GENMAB A/S
09/27GENMAB A/S : RBC Lifts Price Target on Genmab to $56 From $55 Amid Tivdak US Approval, Pot..
MT
09/22GENMAB A/S : (English translation of Articles of Association) (Form 6-K)
PU
09/22GENMAB A/S : Articles of association dated September 21, 2021 – English
PU
09/22PRESS RELEASE : Pfizer and BioNTech Expand -3-
DJ
09/22GENMAB A/S : Investor Presentation - September 2021
PU
09/21GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise (Form 6-K..
PU
09/21Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
09/21SEAGEN : Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin..
AQ
09/21SEAGEN : Genmab Win Accelerated US FDA Nod For Cervical Cancer Drug
MT
09/20GENMAB A/S : TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor,..
PU
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Financials
Sales 2021 8 042 M 1 264 M 1 264 M
Net income 2021 2 268 M 356 M 356 M
Net cash 2021 15 360 M 2 413 M 2 413 M
P/E ratio 2021 82,5x
Yield 2021 -
Capitalization 179 B 28 112 M 28 078 M
EV / Sales 2021 20,3x
EV / Sales 2022 15,1x
Nbr of Employees 1 029
Free-Float 94,9%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 733,00 DKK
Average target price 2 770,87 DKK
Spread / Average Target 1,39%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S10.96%28 112
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582